DRI Healthcare Trust (DHT.UN) Stock Overview
Focuses on managing and growing a portfolio of pharmaceutical royalties. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
DHT.UN Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
DRI Healthcare Trust Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$18.50 |
| 52 Week High | CA$18.56 |
| 52 Week Low | CA$12.80 |
| Beta | 0.65 |
| 1 Month Change | 13.15% |
| 3 Month Change | 10.98% |
| 1 Year Change | 41.11% |
| 3 Year Change | 83.71% |
| 5 Year Change | 89.16% |
| Change since IPO | 48.59% |
Recent News & Updates
Narrative Update • May 26
DHT.UN: Higher Profitability Assumptions Will Support Future Earnings Power
Analysts lifted their price target on DRI Healthcare Trust to CA$23 from CA$22, citing updated views on fair value, profitability and P/E assumptions as reflected in recent research updates. Analyst Commentary Bullish analysts have been steadily revisiting their assumptions on DRI Healthcare Trust, with a series of upward price target revisions over recent research updates.Narrative Update • May 03
DHT.UN: Higher P/E Assumptions Will Support Future Earnings Power
Analysts have nudged their price target on DRI Healthcare Trust higher to CA$21, citing updated assumptions for fair value, revenue growth, profit margins and future P/E as key drivers of the change. Analyst Commentary Recent price target moves on DRI Healthcare Trust point to a more constructive stance from bullish analysts, who are fine tuning their fair value views as they revisit assumptions around earnings power and valuation multiples.Narrative Update • Apr 19
DHT.UN: Higher Revenue And Margin Assumptions Will Support Future Earnings Power
Analysts have lifted their price target on DRI Healthcare Trust to CA$21, a CA$1 increase, citing updated views on revenue growth, profit margins, and forward P/E assumptions that contribute to a slightly revised fair value estimate. Analyst Commentary Bullish analysts have recently adjusted their view on DRI Healthcare Trust, with a higher price target of CA$21 now reflecting updated assumptions on revenue, margins, and forward P/E.Narrative Update • Apr 03
DHT.UN: Higher Fair Value Assumptions And Buybacks Will Support Future Earnings Power
Analysts have increased their CA$ price target on DRI Healthcare Trust by CA$1, citing updated assumptions around fair value, revenue growth, profit margins and future P/E estimates. Analyst Commentary Recent research points to a more constructive stance on DRI Healthcare Trust, with bullish analysts adjusting their CA$ price targets upward as they refresh models for fair value, revenue growth, profit margins and future P/E expectations.Recent updates
Narrative Update • May 26
DHT.UN: Higher Profitability Assumptions Will Support Future Earnings Power
Analysts lifted their price target on DRI Healthcare Trust to CA$23 from CA$22, citing updated views on fair value, profitability and P/E assumptions as reflected in recent research updates. Analyst Commentary Bullish analysts have been steadily revisiting their assumptions on DRI Healthcare Trust, with a series of upward price target revisions over recent research updates.Narrative Update • May 03
DHT.UN: Higher P/E Assumptions Will Support Future Earnings Power
Analysts have nudged their price target on DRI Healthcare Trust higher to CA$21, citing updated assumptions for fair value, revenue growth, profit margins and future P/E as key drivers of the change. Analyst Commentary Recent price target moves on DRI Healthcare Trust point to a more constructive stance from bullish analysts, who are fine tuning their fair value views as they revisit assumptions around earnings power and valuation multiples.Narrative Update • Apr 19
DHT.UN: Higher Revenue And Margin Assumptions Will Support Future Earnings Power
Analysts have lifted their price target on DRI Healthcare Trust to CA$21, a CA$1 increase, citing updated views on revenue growth, profit margins, and forward P/E assumptions that contribute to a slightly revised fair value estimate. Analyst Commentary Bullish analysts have recently adjusted their view on DRI Healthcare Trust, with a higher price target of CA$21 now reflecting updated assumptions on revenue, margins, and forward P/E.Narrative Update • Apr 03
DHT.UN: Higher Fair Value Assumptions And Buybacks Will Support Future Earnings Power
Analysts have increased their CA$ price target on DRI Healthcare Trust by CA$1, citing updated assumptions around fair value, revenue growth, profit margins and future P/E estimates. Analyst Commentary Recent research points to a more constructive stance on DRI Healthcare Trust, with bullish analysts adjusting their CA$ price targets upward as they refresh models for fair value, revenue growth, profit margins and future P/E expectations.Narrative Update • Mar 20
DHT.UN: Higher P/E Assumptions And Buybacks Will Support Future Earnings Power
Analysts have nudged their fair value estimate for DRI Healthcare Trust to CA$22.76 from CA$22.51, citing a higher CA$21 price target and updated assumptions on revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bullish analysts have reacted positively to the latest assumptions for DRI Healthcare Trust, with one firm lifting its price target to CA$21.Narrative Update • Mar 06
DHT.UN: Updated Assumptions And Distribution Policy Will Support Future Earnings Power
Analysts have lifted their price target on DRI Healthcare Trust to CA$21 from CA$20, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E in their models. Analyst Commentary Recent research points to a slightly higher fair value for DRI Healthcare Trust, with bullish analysts now using a CA$21 price target in their models instead of CA$20.Narrative Update • Jan 26
DHT.UN: Higher Revenue And Margin Assumptions Will Support Future Earnings Power
Narrative Update Analysts have lifted their price target on DRI Healthcare Trust to C$19.50 from C$19.00, citing updated assumptions for revenue growth, profit margins and future P/E multiples that support a slightly higher fair value outlook. Analyst Commentary Bullish analysts are signaling slightly stronger confidence in DRI Healthcare Trust, reflected in the updated C$19.50 price target.Narrative Update • Jan 12
DHT.UN: Rising Royalty Cash Flows Will Support Higher Future Earnings Power
Analysts have nudged their average price target for DRI Healthcare Trust higher, with recent moves from C$17.50 to C$19 and then to C$19.50, supported by updated assumptions on fair value, revenue growth, profit margins and future P/E levels. Analyst Commentary Recent research on DRI Healthcare Trust shows a cluster of higher price targets, with bullish analysts lifting their fair value views into the high teens and low C$20s.Narrative Update • Dec 27
DHT.UN: Rising Royalty Cash Flows Will Support Stronger Future Earnings
Analysts have nudged their average price target on DRI Healthcare Trust higher, from about C$19.00 to roughly C$21.00, citing stronger expected revenue growth, improved profit margins, and a lower forward valuation multiple that they say enhances the stock's risk reward profile. Analyst Commentary Bullish analysts have recently revised their models to reflect stronger fundamental execution at DRI Healthcare Trust, lifting price targets to the low C$20 range and reinforcing positive views on the trust's earnings power and cash flow visibility.
Narrative Update • Dec 13
DHT.UN: Future Royalty Acquisitions Will Support Outperformance Versus Current Unit Price
The analyst price target for DRI Healthcare Trust has been modestly increased to approximately C$19.50, reflecting analysts' slightly higher expectations for long term revenue growth and valuation multiples, despite a marginally lower fair value estimate. Analyst Commentary Bullish analysts have recently raised their price targets on DRI Healthcare Trust, signaling growing confidence in the trust's ability to execute on its pipeline of royalty acquisitions and sustain revenue growth.Narrative Update • Nov 28
DHT.UN: Shares Will Benefit From Improved Performance And Outperform Ratings
Analysts have increased their price targets for DRI Healthcare Trust, with recent revisions moving expectations higher by up to C$2 per share. They cite continued positive revenue growth and resilient performance metrics.Narrative Update • Nov 13
DHT.UN: Price Momentum Will Continue As Profit Margins Are Expected To Improve
Analysts have modestly increased their price target for DRI Healthcare Trust, with recent updates moving from approximately C$19 to a range between C$19.50 and C$21. This reflects improved profit margin expectations and an updated outlook on the company’s future performance.Narrative Update • Oct 29
Sustained Profit Margins And Buybacks Will Drive Enduring Market Potential
Analysts have increased their price target for DRI Healthcare Trust, raising it from approximately C$18.82 to C$20.01. They cited improved revenue growth forecasts and stable profitability metrics as key drivers behind the upgrade.
New Narrative • Jan 16
Management Changes And Casgevy Deal Will Diversify Portfolio And Improve Efficiency
Recent management changes and innovative transactions are enhancing efficiency and diversifying the portfolio, supporting sustained revenue growth.Analysis Article • May 18
We Think DRI Healthcare Trust's (TSE:DHT.U) Solid Earnings Are Understated
The recent earnings posted by DRI Healthcare Trust ( TSE:DHT.U ) were solid, but the stock didn't move as much as we...Shareholder Returns
| DHT.UN | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 9.5% | 6.2% | -0.4% |
| 1Y | 41.1% | 65.1% | 32.1% |
Return vs Industry: DHT.UN underperformed the Canadian Pharmaceuticals industry which returned 65.1% over the past year.
Return vs Market: DHT.UN exceeded the Canadian Market which returned 32.1% over the past year.
Price Volatility
| DHT.UN volatility | |
|---|---|
| DHT.UN Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 11.2% |
| Market Average Movement | 10.1% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 3.8% |
Stable Share Price: DHT.UN has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: DHT.UN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 32 | n/a | www.dricapital.com |
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
DRI Healthcare Trust Fundamentals Summary
| DHT.UN fundamental statistics | |
|---|---|
| Market cap | CA$987.56m |
| Earnings (TTM) | -CA$68.85m |
| Revenue (TTM) | CA$273.72m |
3.7x
P/S Ratio-14.8x
P/E RatioIs DHT.UN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DHT.UN income statement (TTM) | |
|---|---|
| Revenue | US$197.59m |
| Cost of Revenue | US$0 |
| Gross Profit | US$197.59m |
| Other Expenses | US$247.29m |
| Earnings | -US$49.70m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 100.00% |
| Net Profit Margin | -25.15% |
| Debt/Equity Ratio | 105.2% |
How did DHT.UN perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield-43%
Payout RatioDoes DHT.UN pay a reliable dividends?
See DHT.UN dividend history and benchmarks| DRI Healthcare Trust dividend dates | |
|---|---|
| Ex Dividend Date | Jun 30 2026 |
| Dividend Pay Date | Jul 20 2026 |
| Days until Ex dividend | 27 days |
| Days until Dividend pay date | 47 days |
Does DHT.UN pay a reliable dividends?
See DHT.UN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/02 23:46 |
| End of Day Share Price | 2026/06/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DRI Healthcare Trust is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Erin Kyle | CIBC Capital Markets |